Inhibrx Biosciences Beneish M-Score Historical Data
The historical data trend for Inhibrx Biosciences's Beneish M-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inhibrx Biosciences Beneish M-Score Chart
|
Inhibrx Biosciences Annual Data
|
|
Trend |
Dec22 |
Dec23 |
Dec24 |
| Beneish M-Score |
|
- |
- |
-8.85 |
|
Inhibrx Biosciences Quarterly Data
|
|
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
Jun24 |
Sep24 |
Dec24 |
Mar25 |
| Beneish M-Score |
Get a 7-Day Free Trial
|
|
|
- |
- |
- |
-8.85 |
-6.73 |
Competitive Comparison of Inhibrx Biosciences's Beneish M-Score
For the Biotechnology subindustry, Inhibrx Biosciences's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inhibrx Biosciences's Beneish M-Score Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Inhibrx Biosciences's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where Inhibrx Biosciences's Beneish M-Score falls into.
Inhibrx Biosciences Beneish M-Score Calculation
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of Inhibrx Biosciences for today is based on a combination of the following eight different indices:
| M | = | -4.84 | + | 0.92 * DSRI | + | 0.528 * GMI | + | 0.404 * AQI | + | 0.892 * SGI | + | 0.115 * DEPI |
| = | -4.84 | + | 0.92 * 6.2757 | + | 0.528 * 1 | + | 0.404 * 0.1823 | + | 0.892 * 0.1122 | + | 0.115 * 0.6637 |
| - | 0.172 * SGAI | + | 4.679 * TATA | - | 0.327 * LVGI |
| - | 0.172 * 33.5293 | + | 4.679 * -0.541368 | - | 0.327 * 0.4421 |
| = | -6.73 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
| This Year (Mar25) TTM: | Last Year (Mar24) TTM: |
Total Receivables was $0.21 Mil.
Revenue was 0 + 0.1 + 0 + 0.1 = $0.20 Mil.
Gross Profit was 0 + 0.1 + 0 + 0.1 = $0.20 Mil.
Total Current Assets was $223.39 Mil.
Total Assets was $242.64 Mil.
Property, Plant and Equipment(Net PPE) was $12.45 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.60 Mil.
Selling, General, & Admin. Expense(SGA) was $123.96 Mil.
Total Current Liabilities was $43.64 Mil.
Long-Term Debt & Capital Lease Obligation was $104.56 Mil.
Net Income was -43.311 + -47.865 + -43.864 + 1858.011 = $1,722.97 Mil.
Non Operating Income was -0.05 + 0.06 + 0.041 + 2021.531 = $2,021.58 Mil.
Cash Flow from Operations was -35.895 + -43.72 + -30.281 + -57.358 = $-167.25 Mil.
|
Total Receivables was $0.30 Mil.
Revenue was 0 + 1.634 + 0.119 + 0.03 = $1.78 Mil.
Gross Profit was 0 + 1.634 + 0.119 + 0.03 = $1.78 Mil.
Total Current Assets was $14.18 Mil.
Total Assets was $28.22 Mil.
Property, Plant and Equipment(Net PPE) was $9.70 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.26 Mil.
Selling, General, & Admin. Expense(SGA) was $32.96 Mil.
Total Current Liabilities was $38.43 Mil.
Long-Term Debt & Capital Lease Obligation was $0.56 Mil.
|
1. DSRI = Days Sales in Receivables Index
Measured as the ratio of Revenue in Total Receivables in year t to year t-1.
A large increase in DSR could be indicative of revenue inflation.
| DSRI | = | (Receivables_t / Revenue_t) | / | (Receivables_t-1 / Revenue_t-1) |
| = | (0.214 / 0.2) | / | (0.304 / 1.783) |
| = | 1.07 | / | 0.170499 |
| | = | 6.2757 |
2. GMI = Gross Margin Index
Measured as the ratio of gross margin in year t-1 to gross margin in year t.
Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.
| GMI | = | GrossMargin_t-1 | / | GrossMargin_t |
| = | (GrossProfit_t-1 / Revenue_t-1) | / | (GrossProfit_t / Revenue_t) |
| = | (1.783 / 1.783) | / | (0.2 / 0.2) |
| = | 1 | / | 1 |
| | = | 1 |
3. AQI = Asset Quality Index
AQI is the ratio of asset quality in year t to year t-1.
Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.
| AQI | = | (1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) | / | (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1) |
| = | (1 - (223.386 + 12.45) / 242.639) | / | (1 - (14.183 + 9.698) / 28.222) |
| = | 0.028038 | / | 0.153816 |
| | = | 0.1823 |
4. SGI = Sales Growth Index
Ratio of Revenue in year t to sales in year t-1.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
| SGI | = | Sales_t | / | Sales_t-1 |
| = | Revenue_t | / | Revenue_t-1 |
| = | 0.2 | / | 1.783 |
| | = | 0.1122 |
5. DEPI = Depreciation Index
Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
| DEPI | = | (Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) | / | (Depreciation_t / (Depreciaton_t + PPE_t)) |
| = | (1.256 / (1.256 + 9.698)) | / | (2.6 / (2.6 + 12.45)) |
| = | 0.114661 | / | 0.172757 |
| | = | 0.6637 |
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.
SGA expenses index > 1 means that the company is becoming less efficient in generate sales.
| SGAI | = | (SGA_t / Sales_t) | / | (SGA_t-1 /Sales_t-1) |
| = | (123.955 / 0.2) | / | (32.958 / 1.783) |
| = | 619.775 | / | 18.484577 |
| | = | 33.5293 |
7. LVGI = Leverage Index
The ratio of total debt to Total Assets in year t relative to yeat t-1.
An LVGI > 1 indicates an increase in leverage
| LVGI | = | ((LTD_t + CurrentLiabilities_t) / TotalAssets_t) | / | ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1) |
| = | ((104.557 + 43.639) / 242.639) | / | ((0.561 + 38.431) / 28.222) |
| = | 0.610767 | / | 1.381617 |
| | = | 0.4421 |
8. TATA = Total Accruals to Total Assets
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
| TATA | = | (IncomefromContinuingOperations_t | - | CashFlowsfromOperations_t) | / | TotalAssets_t |
| = | (NetIncome_t - NonOperatingIncome_t | - | CashFlowsfromOperations_t) | / | TotalAssets_t |
| = | (1722.971 - 2021.582 | - | -167.254) | / | 242.639 |
| | = | -0.541368 |
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Inhibrx Biosciences has a M-score of -6.73 suggests that the company is unlikely to be a manipulator.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INBX has been successfully added to your